Directional improvements in markers of iron homeostasis and erythropoiesis that are associated with iron overload (hepcidin, erythroferrone, sTfR, erythropoietin, and reticulocyte percentage, as well as LIC by MRI) were observed in patients treated with mitapivat from baseline to week 24 in the M/M arm and were sustained from week 24 to week 96 in the LTE (Table 1). This evidence concerns the gene EPO and Tangier disease.